Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
One week countdown to the 2026 World Cup: Spain and France are the joint favorites to win on Predict.fun, with England and Portugal close behind.

One week countdown to the 2026 World Cup: Spain and France are the joint favorites to win on Predict.fun, with England and Portugal close behind.

Odaily星球日报Odaily星球日报2026/06/05 08:08
Show original

In the Predict.fun "2026 World Cup Winner" prediction event, Spain and France tie for first place with a 17% chance each, England is in second place with a 12% chance of winning, and Portugal closely follows with a 10% chance. So far, the total contract trading volume for the Predict.fun "2026 World Cup Winner" event has exceeded $260 million.

The 2026 World Cup will officially kick off at 3:00 a.m. (GMT+8) on Friday, June 12. This edition of the World Cup will be jointly hosted by the United States, Mexico, and Canada—the first World Cup in history to be co-hosted by three countries—and the number of participating teams will be expanded to 48.

Keep following prediction markets—see the change before the price is set.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage